Breast Cancer Clinical Trials in Santa Monica, California

7 studies are recruiting for breast cancer in Santa Monica, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

   This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Santa Monica, California

   Locations

   67 in total

   Run by

   AstraZeneca

   See if you can join NCT05123482 on ClinicalTrials.gov

2. Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

   Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people toler…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UCLA Hematology/Oncology - Parkside ( Site 0021), Santa Monica, California

   Locations

   17 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06797635 on ClinicalTrials.gov

3. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

   This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   St. John's Cancer Center, Santa Monica, California

   Locations

   79 in total

   Run by

   BriaCell Therapeutics Corporation

   See if you can join NCT06072612 on ClinicalTrials.gov

4. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

   Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Santa Monica, California

   Locations

   23 in total

   Run by

   AstraZeneca

   See if you can join NCT05877599 on ClinicalTrials.gov

5. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

   This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   University of California Los Angeles - Hematology / Oncology Parkside, Santa Monica, California

   Locations

   179 in total

   Run by

   Greenwich LifeSciences, Inc.

   See if you can join NCT05232916 on ClinicalTrials.gov

6. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

   A Study of Emi-Le in Participants with Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA David Geffen School of Medicine, Division of Hematology/Oncology, Santa Monica, California

   Locations

   26 in total

   Run by

   Day One Biopharmaceuticals, Inc.

   See if you can join NCT05377996 on ClinicalTrials.gov

7. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Santa Monica, Santa Monica, California

   Locations

   39 in total

   Run by

   SystImmune Inc.

   See if you can join NCT05983432 on ClinicalTrials.gov